Frehepta Tablet 80 mg contains Resmetirom, an innovative oral medication belonging to a new class of liver‑directed agents known as thyroid hormone receptor‑β (THR‑β) agonists. This prescription medicine is designed to treat specific forms of nonalcoholic steatohepatitis (NASH)—a progressive fatty liver disease—by targeting the underlying causes rather than only relieving symptoms. It offers a promising treatment option for adults with moderate to advanced liver fibrosis associated with NASH, when used alongside lifestyle interventions such as diet and exercise.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Frehepta Tablet 80 mg is indicated for:

• Treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) in adults with evidence of moderate to advanced liver fibrosis (stages F2–F3), in conjunction with diet and exercise.

This condition—often linked with metabolic dysfunction and obesity—can lead to significant liver damage, including inflammation and fibrosis, if untreated. Resmetirom represents one of the first disease‑specific therapies targeting this challenging condition.

Therapeutic Class

Liver‑Directed Metabolic Agent / Thyroid Hormone Receptor‑β Agonist

Pharmacology

Resmetirom selectively stimulates thyroid hormone receptors beta (THR‑β), which are predominantly located in the liver. Activation of THR‑β enhances hepatic fat metabolism and reduces the pathological buildup of triglycerides in liver cells. By improving lipid metabolism and lowering intrahepatic fat, resmetirom helps mitigate inflammation and fibrotic changes associated with NASH. This mechanism is targeted to the liver, limiting systemic effects on the heart and bones that are seen with broader thyroid hormone therapies.

Dosage and Administration

• Adults (<100 kg body weight): 80 mg taken orally once daily.

• Adults (≥100 kg body weight): Dose may be adjusted up to 100 mg once daily based on clinical response and physician assessment.

Frehepta can be taken with or without food. The tablet should be swallowed whole and not crushed or chewed. Treatment decisions should be individualized and supervised by a qualified healthcare provider.

Drug Interactions

Resmetirom is metabolized by liver enzymes and may interact with drugs that strongly influence enzymes like CYP2C8 and organic anion‑transporting polypeptides (OATP1B1/OATP1B3). Co‑administration of strong enzyme inhibitors can increase resmetirom levels and the risk of side effects. Dose adjustments may be necessary when used with medications such as gemfibrozil or clopidogrel, and statin doses may require modification due to increased plasma concentrations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Frehepta is contraindicated in patients with known hypersensitivity to resmetirom or any of the tablet’s components. It is not recommended for use in individuals with decompensated cirrhosis or severe hepatic impairment, as safety and efficacy in these populations have not been established.

Side Effects

Common side effects observed with resmetirom include:

• Diarrhea

• Nausea

• Abdominal discomfort

• Itching (pruritus)

• Constipation

• Dizziness

Serious adverse effects are uncommon but may include liver enzyme elevations, gallbladder disease (such as cholelithiasis or cholecystitis), and pancreatitis. Liver function should be monitored regularly during treatment.

Pregnancy and Lactation

The safety of resmetirom in pregnancy and lactation is not well established. Use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult with a healthcare provider before using this medication.

Precautions and Warnings

• Liver Monitoring: Regular monitoring of liver function tests is recommended due to potential hepatotoxicity.

• Not for Acute Relief: Frehepta is not intended for immediate symptom relief but for long‑term disease modification.

• Lifestyle Measures: Continued emphasis on diet, exercise, and metabolic risk factor control is essential for successful management of NASH.

Use in Special Populations

• Hepatic Impairment: Not recommended in moderate to severe impairment.

• Elderly: Dose selection should account for increased sensitivity to adverse effects and comorbid conditions.